Vascular integrins in tumor angiogenesis: mediators and therapeutic targets

Area of Science:

• Oncology
• Vascular Biology
• Drug Discovery

Background:

• Tumor angiogenesis, the growth of new blood vessels in tumors, is a critical factor in cancer progression.
• The concept of targeting tumor angiogenesis for cancer therapy was pioneered by Dr. Judah Folkman.
• The approval of Avastin (bevacizumab) validated antiangiogenic strategies, spurring research into new targets.

Purpose of the Study:

• To review the role of integrins in angiogenesis.
• To present recent developments in targeting alphaVbeta3 and alpha5beta1 integrins for cancer therapy.
• To discuss future perspectives for integrin-targeted antiangiogenic drugs.

Main Methods:

• Review of preclinical and clinical evidence on vascular integrins as therapeutic targets.
• Pharmacological inhibition of integrin function in preclinical models.
• Evaluation of low-molecular-weight integrin inhibitors and function-blocking antibodies in clinical studies.

Main Results:

• Preclinical studies demonstrated that integrin inhibition suppresses angiogenesis and tumor progression.
• alphaVbeta3 and alphaVbeta5 were identified as early targets, with additional integrins like alpha1beta1, alpha2beta1, alpha5beta1, and alpha6beta4 emerging as potential targets.
• Clinical trials showed low toxicity and good tolerability for integrin inhibitors, supporting their use in combination therapies.

Conclusions:

• Vascular integrins represent promising therapeutic targets for antiangiogenic cancer therapy.
• Integrin antagonists, including small molecules and antibodies, have shown efficacy and safety in preclinical and clinical settings.
• Further research and clinical trials are warranted to optimize integrin-targeted therapies for cancer treatment, potentially in combination with standard treatments.